Search alternatives:
mean decrease » a decrease (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
wt decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
Showing 661 - 680 results of 32,589 for search '(( 50 ((ns decrease) OR (we decrease)) ) OR ( 5 ((wt decrease) OR (mean decrease)) ))', query time: 0.81s Refine Results
  1. 661
    Mean pain interference overtime (baseline to 12 weeks).

    Mean pain interference overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 662
    Mean pain severity overtime (baseline to 12 weeks).

    Mean pain severity overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 663
    Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session.

    Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

    Published 2025
    Save to List
    Saved in:
  4. 664
    Y86 is critical for SERINC3/5 antagonism by SIVcol Nef.

    Y86 is critical for SERINC3/5 antagonism by SIVcol Nef. by Dorota Kmiec (5646374)

    Published 2018
    Save to List
    Saved in:
  5. 665
    <i>In vivo</i> HDL protects the heart from IR injury via STAT3 activation.

    <i>In vivo</i> HDL protects the heart from IR injury via STAT3 activation. by Sarah Pedretti (703288)

    Published 2019
    Save to List
    Saved in:
  6. 666
    Fig 5 -

    Fig 5 - by Harshita Sharma (4836180)

    Published 2023
    Save to List
    Saved in:
  7. 667
    Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced respiratory burst.

    Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced respiratory burst. by Jian Hao (160736)

    Published 2013
    Save to List
    Saved in:
  8. 668
    Physiological characterization of rice <i>m167</i> plants.

    Physiological characterization of rice <i>m167</i> plants. by Xuexia Wang (3701098)

    Published 2017
    Save to List
    Saved in:
  9. 669
    AA-deficient <i>sfx</i> mice had decreased articular cartilage.

    AA-deficient <i>sfx</i> mice had decreased articular cartilage. by Richard C. Lindsey (7148168)

    Published 2019
    Save to List
    Saved in:
  10. 670
    Gut microbiota modulates fecal metabolomic profiles in Atm-KO and WT mice.

    Gut microbiota modulates fecal metabolomic profiles in Atm-KO and WT mice. by Amrita K. Cheema (515119)

    Published 2016
    Save to List
    Saved in:
  11. 671
    Type and duration of leisure-time activities performed 5 years after RYGB.

    Type and duration of leisure-time activities performed 5 years after RYGB. by Alice Bellicha (3583493)

    Published 2022
    Save to List
    Saved in:
  12. 672
    Means and Cronbach’s alphas for 5C and VAX-measured vaccination attitudes over 12 months.

    Means and Cronbach’s alphas for 5C and VAX-measured vaccination attitudes over 12 months. by Allyson J. Gallant (9382396)

    Published 2021
    Save to List
    Saved in:
  13. 673
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 674
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 675
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 676
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 677
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 678
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 679
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 680
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: